Project applications with a clear innovation content and implementation plans in biotech areas like medicine, bioinformatics, pharmaceutical products and services, life sciences, digitalisation, or (bio)process technology (non-exhaustive list of cooperation areas) are welcome.

The Biotech Call for Network Projects is dedicated to foster biotech-related cooperation between the listed countries: Austira, Belgium, Canada, Chile, France, Germany, Lithuania, The Netherlands, Portugal, South Africa, South Korea, Spain, Switzerland, Türkye. Partners from countries that are not listed are welcome to join consortia if they organise their own national funding or self-finance their project work.

HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research (RIA)

HORIZON-MISS-2026-02-CANCER-02: Microbiome for early cancer prediction before the onset of disease (RIA)

HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers (RIA)

HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care (RIA)

HORIZON-MISS-2026-02-CANCER-05: Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre  (ECPDC) (IA)

HORIZON-MISS-2026-02-CANCER-06: Development of a research capacity building programme on cancer with and for Ukraine (CSA)

HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients (RIA)

The call opens on 10th February 2026

The ECTC aims to support multinational, Good Clinical Practice (GCP)‑compliant Phase I, Phase I/II and Phase II interventional clinical trialsin rare diseases. The purpose is to generate robust clinical evidence and, where appropriate, data of regulatory relevance to support future interactions with regulatory authorities and subsequent clinical development.

Building on the progress made through previous EDCTP initiatives, this call aims to scale and sustain these efforts by establishing training, twinning, and innovation networks, leveraging existing networks where applicable that will bolster workforce capacity in ethics, regulatory, and PV and harmonisation of processes and timelines. Central to this approach is the development of a robust digital health ecosystem, which will allow seamless collaboration and enhance the operational efficiency and responsiveness of ethics, regulatory, and PV frameworks through the integration of data-driven technologies and digital infrastructure, including artificial intelligence (AI) when considered appropriate, catalysing the approval and implementation of health solutions in SSA.

By aligning with these strategic directions, this CSA promotes a shared vision: one where digital innovation strengthens local health systems rather than working in silos. The goal is not to create new technologies, but to make better use of what already exists by improving coordination, strengthening human capacity, and supporting evidence-based policies and investments that can unlock the true potential of digital health across the region.

The HaDEA procurement HADEA/2026/OP/0019-PIN aims to ensure clinical trial preparedness for Filovirus (Marburg (MARV) and/or Ebola Sudan (SUDV)) outbreaks through the establishment of an EU-based reserve of investigational vaccines as a critical preparedness measure, given the sporadic yet high-consequence nature of these pathogens.

Deadline for submitting pre-proposals is 21st July 2026

TRANSCAN-4, in continuity of the preceding ERA-NET TRANSCAN-3, has the goal of coordinating national and regional funding programmes for research in the area of translational cancer research. The specific challenge is to promote a transnational collaborative approach between scientific teams in demanding areas of translational cancer research to ensure a more efficient use of available resources (e.g. data, infrastructures) and ultimately to produce results of higher quality and impact.

• CP-p-25-35: „Manufacturing investments and manufacturing capacity reservation contracts to strengthen supply of medical countermeasures“ (coming in Q1)
• CP-p-25-36: „Support to speed up the development of, access to and/or uptake of medical countermeasures“ (coming in Q2)

Medical and health research: Telemedicine, biomedical research

Sub-topic 1: Adoption of telemedicine for remote healthcare solutions 

Sub-topic 2: Innovative research on cellular signaling pathways for biomedical applications 

The Call is open to legal entities, including institutions, organisations, and enterprises, registered in one of the following countries: Austria, Czech Republic, Estonia, Finland, Germany, Latvia, Republic of Moldova, Poland, Romania, Türkiye and Ukraine. 

The overall objective of the EIC Pathfinder for advanced research is to develop the scientific basis to underpin breakthrough technologies. It provides support for the earliest stages of scientific, technological or deep tech research and development. Pathfinder projects aim to build on new, cutting-edge directions in science and technology to disrupt a field and a market or create new opportunities by realising innovative technological solutions.

EIT Health is calling for innovative digital and AI-powered medical technologies that are at an Innovation Maturity Level (IML) 6 and ready for clinical validation and market launch. Selected projects will be awarded funding to run pivotal clinical studies, collect real-world evidence to demonstrate safety and efficacy, apply for regulatory approval, and prepare for market commercialisation.

The New Models to Deliver Healthcare (NMDH) Call aims to bridge the gap between proven, market-ready health solutions at Innovation Maturity Level (IML) 8 to 9 and their adoption in real-world healthcare systems. This call offers funding for collaborative, industry-led, payor-supported and patient-centric projects that implement and scale value-based healthcare models.

IHI call 12 will be an one-stage call for proposals with the following topics:

• HORIZON-JU-IHI-2026-12-01: Boosting innovation for a better understanding of    the determinants of health
• HORIZON-JU-IHI-2026-12-02: Boosting innovation through better integration of fragmented health R&I efforts
• HORIZON-JU-IHI-2026-12-03: Boosting innovation for peopled centred integrated healthcare solutions
• HORIZON-JU-IHI-2026-12-04: Boosting innovation through exploitation of digitalisation and data exchange in healthcare
• HORIZON-JU-IHI-2026-12-05: Boosting innovation for better assessment of the added value of innovative integrated healthcare solutions

HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches (PPI)

HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems (RIA)

HORIZON-HLTH-2026-04-CARE-04: Enhancing and enlarging the European Partnership on Personalised Medicine (EP PerMEd) (Top-up) (Programme Cofund Actions)

The call opens on 10th February 2026

HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults (RIA)

HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions (RIA)

HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential (RIA)

HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD) (RIA)

HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways (RIA)

HORIZON-HLTH-2026-02-DISEASE-12: European Partnership on Rare Diseases (ERDERA) (Phase 2) (Programme Cofund Actions)

HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health (CSA)

The call opens on 10th February 2026.